Advanced search

Online first
Review Article
Published online: 2025-02-25

open access

View PDF Download PDF file
Supp./Additional Files
Page views 265
Article views/downloads 131
Get Citation

Connect on Social Media

Connect on Social Media

Galectin-3: Heart failure biomarker in pediatric heart defects

Daniel Gondko1, Patrycja Dębiec1, Jakub Roman1, Nikodem Pietrzak1, Krzysztof Kocot1, Jacek Kusa1
DOI: 10.5603/cj.99070
Pubmed: 39998403

Abstract

Galectin-3 (Gal-3), a β-galactoside-binding lectin, has emerged as a potential diagnostic and prognostic biomarker for various diseases, including certain heart and kidney diseases, as well as cancer. Its significance is particularly notable in the context of congenital heart defects (CHD), which are the most prevalent congenital malformations, occurring in 6 to 8 out of every 1000 live births. Symptoms of heart failure (HF) in patients with congenital heart defects can manifest early in life, but in some cases, the disease progresses gradually, leading to a gradual decline in quality of life and the development of various complications. This variability underscores the need for early biomarkers to detect HF development in pediatric patients. Gal-3 plays a key role in myocardial remodeling, making it a promising candidate for advancing the diagnosis and management of HF in CHD patients. It is especially relevant in pediatric care, where early detection and intervention can significantly alter disease progression and patient outcomes. This review aims to consolidate current knowledge on the utility of Gal-3 in predicting HF among pediatric patients with CHD, highlighting its potential in changing the direction of diagnosis and treatment in this vulnerable patient population.

Keywords: galectin-3congenital heart defectsheart failurebiomarkers

Article available in PDF format

View PDF Download PDF file

References

  1. Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease: A scientific statement from the american heart association. Circulation. 2016; 133(8): 770–801.
    CrossRefPubMed
  2. Kurmani S, Squire I. Acute heart failure: Definition, classification and epidemiology. Curr Heart Fail Rep. 2017; 14(5): 385–392.
    CrossRefPubMed
  3. Jayaprasad N. Heart failure in children. Heart Views. 2016; 17(3): 92–99.
    CrossRefPubMed
  4. Hsu D, Pearson G. Heart failure in children. Circ Heart Fail. 2009; 2(1): 63–70.
    CrossRefPubMed
  5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
    CrossRefPubMed
  6. Benavidez OJ, Gauvreau K, Geva T. Diagnostic errors in congenital echocardiography: importance of study conditions. J Am Soc Echocardiogr. 2014; 27(6): 616–623.
    CrossRefPubMed
  7. Saraf RP, Suresh Pv, Maheshwari S, et al. Pediatric echocardiograms performed at primary centers: Diagnostic errors and missing links! Ann Pediatr Cardiol. 2015; 8(1): 20–24.
    CrossRefPubMed
  8. Panagopoulou V, Deftereos S, Kossyvakis C, et al. NTproBNP: An important biomarker in cardiac diseases. Curr Top Med Chem. 2013; 13(2): 82–94.
    CrossRefPubMed
  9. Argüeso P, Panjwani N. Focus on molecules: Galectin-3. Exp Eye Res. 2011; 92(1): 2–3.
    CrossRefPubMed
  10. Newlaczyl AU, Yu LG. Galectin-3 — a jack-of-all-trades in cancer. Cancer Lett. 2011; 313(2): 123–128.
    CrossRefPubMed
  11. Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem. 1999; 264(2): 569–576.
    CrossRefPubMed
  12. Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016; 1863(3): 427–437.
    CrossRefPubMed
  13. de Oliveira FL, Gatto M, Bassi N, et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015; 240(8): 1019–1028.
    CrossRefPubMed
  14. Dumic J, Dabelic S, Flögel M. Galectin-3: An open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–635.
    CrossRefPubMed
  15. Issa SF, Christensen AF, Lottenburger T, et al. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015; 82(1): 70–75.
    CrossRefPubMed
  16. Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018; 41(2): 599–614.
    CrossRefPubMed
  17. Oosterhof T, Tulevski II, Vliegen HW, et al. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol. 2006; 97(7): 1051–1055.
    CrossRefPubMed
  18. Kowalik E, Kuśmierczyk-Droszcz B, Klisiewicz A, et al. Galectin-3 plasma levels in adult congenital heart disease and the pressure overloaded right ventricle: reason matters. Biomark Med. 2020; 14(13): 1197–1205.
    CrossRefPubMed
  19. Slack RJ, Mills R, Mackinnon AC. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int J Biochem Cell Biol. 2021; 130: 105881.
    CrossRefPubMed
  20. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
    CrossRefPubMed
  21. Guzel S, Serin O, Guzel E, et al. Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. Korean J Intern Med. 2013; 28(3): 386.
    CrossRef
  22. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2): 288–298.
    CrossRefPubMed
  23. Song X, Qian X, Shen M, et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta. 2015; 1853(2): 513–521.
    CrossRefPubMed
  24. Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, et al. Association between CRP and tnf-α genes variants and cardiovascular heart disease in a Mexican population: protocol for a case-control study. Int J Environ Res Public Health. 2016; 13(1): 103.
    CrossRefPubMed
  25. Tsigkou V, Siasos G, Oikonomou E, et al. The prognostic role of galectin-3 and endothelial function in patients with heart failure. Cardiol J. 2023; 30(5): 725–733.
    CrossRefPubMed
  26. South K, Lane DA. ADAMTS-13 and von Willebrand factor: A dynamic duo. J Thromb Haemost. 2018; 16(1): 6–18.
    CrossRefPubMed
  27. He J, Li X, Luo H, et al. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. J Am Soc Hypertens. 2017; 11(5): 275–289.e2.
    CrossRefPubMed
  28. Ibarrola J, Arrieta V, Sádaba R, et al. Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: A new pathway to induce cardiac damage. Clin Sci (Lond). 2018; 132(13): 1471–1485.
    CrossRefPubMed
  29. Ibarrola J, Sádaba R, Garcia-Peña A, et al. A role for fumarate hydratase in mediating oxidative effects of galectin-3 in human cardiac fibroblasts. Int J Cardiol. 2018; 258: 217–223.
    CrossRefPubMed
  30. Belch JJ, Bridges AB, Scott N, et al. Oxygen free radicals and congestive heart failure. Br Heart J. 1991; 65(5): 245–248.
    CrossRefPubMed
  31. Zhong X, Qian X, Chen G, et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019; 46(3): 197–203.
    CrossRefPubMed
  32. Wu CK, Su MY, Lee JK, et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep. 2015; 5: 17007.
    CrossRefPubMed
  33. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372(71): 103–112.
    CrossRefPubMed
  34. CASP UK. CASP systematic review checklist [Internet]. Oxford: CASP UK; 2018: 4. https://casp-uk.net/wp-content/uploads/2018/01/CASP-Systematic-Review-Checklist_2018.pdf (18.01.2020).
  35. Saleh N, Khattab A, Rizk M, et al. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: A prospective study. BMC Pediatr. 2020; 20(1): 537.
    CrossRefPubMed
  36. Elhewala AAS, Ibrahem MM, Abdel Hafez ES. Galectin-3 as a biomarker of heart failure in children with congenital heart disease. Egypt J Hosp Med. 2020; 80(3): 1008–1013.
    CrossRef
  37. Parker DM, Everett AD, Stabler ME, et al. Novel biomarkers improve prediction of 365-day readmission after pediatric congenital heart surgery. Ann Thorac Surg. 2020; 109(1): 164–170.
    CrossRefPubMed
  38. Cura C, Argun M, Koçer D. Aldosterone, galectin-3, and NTproBNP levels and their values as biomarkers in infants with ventricular septal defect. Turk Kardiyol Dern Ars. 2022; 50(2): 131–138.
    CrossRefPubMed
  39. Yang Q, Chen H, Correa A, et al. Racial differences in infant mortality attributable to birth defects in the United States, 1989–2002. Birth Defects Res A Clin Mol Teratol. 2006; 76(10): 706–713.
    CrossRefPubMed
  40. Mackie AS, Gauvreau K, Newburger JW, et al. Risk factors for readmission after neonatal cardiac surgery. Ann Thorac Surg. 2004; 78(6): 1972–1978; discussion 1978.
    CrossRefPubMed
  41. Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011; 306(15): 1688–1698.
    CrossRefPubMed
  42. Tregay J, Wray Jo, Bull C, et al. Unexpected deaths and unplanned re-admissions in infants discharged home after cardiac surgery: A systematic review of potential risk factors. Cardiol Young. 2015; 25(5): 839–852.
    CrossRefPubMed
  43. Brown JR, Stabler ME, Parker DM, et al. Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery. Cardiol Young. 2019; 29(8): 1051–1056.
    CrossRefPubMed
  44. Parker DM, Everett AD, Stabler ME, et al. Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery. J Card Surg. 2019; 34(5): 329–336.
    CrossRefPubMed
  45. Gersony WM. Fontan operation after 3 decades: what we have learned. Circulation. 2008; 117(1): 13–15.
    CrossRefPubMed
  46. van den Bosch E, Bossers SSM, Kamphuis VP, et al. Associations between blood biomarkers, cardiac function, and adverse outcome in a young fontan cohort. J Am Heart Assoc. 2021; 10(5): e015022.
    CrossRefPubMed
  47. van der Ven JPG, van den Bosch E, Bogers AdJ, et al. Current outcomes and treatment of tetralogy of Fallot. F1000Res. 2019; 8: 1530.
    CrossRefPubMed
  48. Luijten LWG, van den Bosch E, Duppen N, et al. Long-term outcomes of transatrial-transpulmonary repair of tetralogy of Fallot. Eur J Cardiothorac Surg. 2015; 47(3): 527–534.
    CrossRefPubMed
  49. van den Bosch E, van Genuchten WJ, Luijnenburg SE, et al. Associations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort. Int J Cardiol. 2022; 361: 31–37.
    CrossRefPubMed
  50. DiLorenzo MP, DeCost G, Mai AD, et al. Comparison of serum biomarkers of myocardial fibrosis with cardiac magnetic resonance in patients operated for tetralogy of Fallot. Int J Cardiol. 2022; 358: 27–33.
    CrossRefPubMed
  51. Hoffman JIE, Kaplan S, Liberthson RR, et al. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39(12): 1890–1900.
    CrossRefPubMed
  52. Bocelli A, Favilli S, Pollini I, et al. Prevalence and long-term predictors of left ventricular hypertrophy, late hypertension, and hypertensive response to exercise after successful aortic coarctation repair. Pediatr Cardiol. 2013; 34(3): 620–629.
    CrossRefPubMed
  53. Klitsie LM, Roest AAW, Kuipers IM, et al. Blood pressure response during exercise in children, adolescents and young adults with a history of aortic coarctation repair. J Hypertens. 2014; 32(7): 1548–1556.
  54. Crepaz R, Cemin R, Romeo C, et al. Factors affecting left ventricular remodelling and mechanics in the long-term follow-up after successful repair of aortic coarctation. Cardiol Young. 2005; 15(2): 160–167.
    CrossRefPubMed
  55. Frank BS, Urban TT, Lewis K, et al. Circulating biomarkers of left ventricular hypertrophy in pediatric coarctation of the aorta. Congenit Heart Dis. 2019; 14(3): 446–453.
    CrossRefPubMed
  56. Oeun B, Nakatani D, Hikoso S, et al. Osaka CardioVascular Conference (OCVC) Heart Failure Investigators. Factors associated with elevated N-terminal pro B-type natriuretic peptide concentrations at the convalescent stage and 1-year outcomes in patients with heart failure with preserved ejection fraction. Circ Rep. 2020; 2(8): 400–408.
    CrossRefPubMed
  57. Jering KS, Claggett BL, Pfeffer MA, et al. Prognostic importance of NT-proBNP (N-terminal pro-b-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circ Heart Fail. 2023; 16(5): e010259.
    CrossRefPubMed
  58. Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010; 6: 411–418.
    CrossRefPubMed
  59. Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022; 27(2): 625–643.
    CrossRefPubMed
  60. Zaborska B, Sikora-Frąc M, Smarż K, et al. The role of galectin-3 in heart failure-the diagnostic, prognostic and therapeutic potential-where do we stand? Int J Mol Sci. 2023; 24(17): 13111.
    CrossRefPubMed
  61. Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014; 44(3): 303–308.
    CrossRefPubMed
  62. Tsutamoto T, Sakai H, Yamamoto T, et al. Renal clearance of N-terminal pro-brain natriuretic peptide is markedly decreased in chronic kidney disease. Circ Rep. 2019; 1(8): 326–332.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note